Loading...
The all-virtual 2021 Gastrointestinal Cancers Symposium (January 15–17, 2021) included presentations on promising new agents, reports of outcomes with combined-modality therapy, and updates on pivotal trials. NEJM Journal Watch Oncology and Hematology Associate Editor David H. Ilson, MD, PhD, summarizes key findings. Abstracts from the symposium can be found in the meeting library.
Wainberg and colleagues presented results from the phase 2 FIGHT trial, an industry-sponsored, double-blind randomized controlled trial in which 155 patients with confirmed fibroblast growth factor receptor (FGFR) 2b–positive advanced gastric cancer received first-line chemotherapy with mFOLFOX6 plus eit…